Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nivolumab, pembrolizumab successfully used in Kaposi sarcoma

Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Key clinical point: Checkpoint inhibitor therapy is effective for patients with HIV-associated Kaposi sarcoma.

Major finding: Two-thirds of patients (67%) with HIV-associated Kaposi sarcoma achieved partial or complete remission when treated with immune checkpoint blockade.

Study details: A retrospective study involving nine patients with Kaposi sarcoma treated with either nivolumab or pembrolizumab at the Rebecca and John Moores Cancer Center at the University of California, San Diego, (UCSD) from August 2013 through December 2017.

Disclosures: Authors reported compensation from Incyte, Genentech, Merck, Pfizer, and others.

Source: Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Citation:

Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Must Reads in Sarcoma & GIST

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

Expanded genetic analyses of myxofibrosarcomas may guide precision therapies, Ogura K et al. Nature Communications; 17 July 2018. https://doi.org/10.1038/s41467-018-03891-9

Malignant tenosynovial giant cell tumors appear to originate from synoviocytes, Al-Ibraheemi A et al. Modern Pathology; 11 Sept. 2018. https://doi.org/10.1038/s41379-018-0129-0

Type and rate of clonal evolution vary widely in sarcoma pathogenetic subgroups, Hofvander J et al. Nature Communications 10 Sept. 2018. https://doi.org/10.1038/s41467-018-06098-0

Increasing pannexin 1 levels might be a novel treatment for rhabdomyosarcoma , Xiang X et al. Oncogenesis; 21 Nov. 2018. https://doi.org/10.1038/s41389-018-0100-4